ArticleZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology2019
[Chinese Clinical Practice Guidelines for transarterial chemoembolization of hepatocellular carcinoma].
Article in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Clinical outcomes and prognostic factors of systemic therapy combined with interventional treatment in hepatocellular carcinoma: a multicenter retrospective case series.Translational cancer research · 2026Article
- Quantitative determination of embolization endpoints based on local arterial pressure.Bioengineering & translational medicine · 2026Article
- The PLANES model for unresectable hepatocellular carcinoma treated with transcatheter arterial chemoembolization plus lenvatinib and PD-1 inhibitors: a multicenter, retrospective study.Frontiers in immunology · 2025Article
- [Clinical study on early predictors of concurrent bile duct injury following TACE in patients with liver cancer].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2023Article
- Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001).Signal transduction and targeted therapy · 2023Article
- Transradial versus transfemoral approach for TACE: a retrospective study.BMC gastroenterology · 2023Article
- Adjuvant transarterial chemoembolization timing after radical resection is an independent prognostic factor for patients with hepatocellular carcinoma.Frontiers in oncology · 2023Article
- Efficacy and Safety of Lobaplatin-TACE in the Treatment of Primary Hepatocellular Carcinoma: A Retrospective Study.Anti-cancer agents in medicinal chemistry · 2023Article
- [Research progress of adjuvant TACE therapy for liver cancer after radical resection].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2022Review
- Prophylactic Use of Antibiotics for Postsurgical Infection in c-TACE and DEB-TACE High-Risk Patients: A Case-Control Study.Journal of healthcare engineering · 2022Article
- An evaluation of the reporting quality in clinical practice guidelines for hepatocellular carcinoma using the RIGHT checklist.Annals of translational medicine · 2021Article
- Efficacy and Safety of Transarterial Chemoembolization in Elderly Patients of Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Retrospective Study.Frontiers in oncology · 2021Article
- [Minimally invasive therapies for hepatocellular carcinoma].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is a malignant tumor originating from liver cells. Hepatitis B virus (HBV) infection is the main cause of HCC in 80% of Chinese patients. Pathologically, HCC is usually a kind of tumor with rich blood supply. Transarterial chemoembolization (TACE) can block the blood supply of the tumor, besides, high concentration of chemotherapeutic drugs can be accumulated within the tumor, and therefore TACE can kill tumor cells to the maximum extent. TACE has been recognized as one of the most commonly used non-surgical treatments for HCC. In view of this, after in-depth discussion the expertsfrom Chinese College of Interventionalists, Chinese Medical Doctor Association, put forward,《Chinese clinical practice guidelines for transarterial chemoembolization of hepatocellular carcinoma》. This《Guidelines》contains the following contents about TACE: brief introduction of HCC, indications and contraindications, perioperative treatment, euipment and drug preparation, ethical and informed consent, preparation of the patients, procedure,complications and management, evaluation and follow-up, and comprehensive therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.